Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy; Ibrahim Aldoss; Matthew C. Foster; Peter H. Sayre; Matthew J. Wieduwilt; Anjali S. Advani; John E. Godwin; Martha L. Arellano; Kendra L. Sweet; Ashkan Emadi; Farhad Ravandi; Harry P. Erba; Michael Byrne; Laura Michaelis; Max S. Topp; Norbert Vey; Fabio Ciceri; Matteo Giovanni Carrabba; Stefania Paolini; Gerwin A. Huls; Mojca Jongen-Lavrencic; Martin Wermke; Patrice Chevallier; Emmanuel Gyan; Christian Recher; Patrick J. Stiff; Kristen M. Pettit; Bob Lowenberg; Sarah E. Church; Erica Anderson; Jayakumar Vadakekolathu; Marianne Santaguida; Michael P. Rettig; John Muth; Teia Curtis; Erin Fehr; Kuo Guo; Jian Zhao; Ouiam Bakkacha; Kenneth Jacobs; Kathy Tran; Patrick Kaminker; Maya Kostova; Ezio Bonvini; Roland B. Walter; Jan K. Davidson-Moncada; Sergio Rutella; John F. DiPersio

doi:10.1182/blood.2020007732

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy
, Ibrahim Aldoss
, Matthew C. Foster
, Peter H. Sayre
, Matthew J. Wieduwilt
, Anjali S. Advani
, John E. Godwin
, Martha L. Arellano
, Kendra L. Sweet
, Ashkan Emadi
, Farhad Ravandi
, Harry P. Erba
, Michael Byrne
, Laura Michaelis
, Max S. Topp
, Norbert Vey
, Fabio Ciceri
, Matteo Giovanni Carrabba
, Stefania Paolini
, Gerwin A. Huls

Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Recher, Patrick J. Stiff, Kristen M. Pettit, Bob Lowenberg, Sarah E. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella^*, John F. DiPersio

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

284 Citations (Scopus)

161 Downloads (Pure)

Abstract

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure IPIF1) or relapse after

Original language	English
Pages (from-to)	751-762
Number of pages	12
Journal	Blood
Volume	137
Issue number	6
DOIs	https://doi.org/10.1182/blood.2020007732
Publication status	Published - 11-Feb-2021

Keywords

CYTOKINE RELEASE SYNDROME
RECEPTOR T-CELLS
MYELODYSPLASTIC SYNDROME
PHASE-II
CYTARABINE
DIAGNOSIS
CRITERIA
RECOMMENDATIONS
BLINATUMOMAB
FLUDARABINE

Access to Document

10.1182/blood.2020007732

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaFinal publisher's version, 2.2 MBLicence: Taverne

Handle.net

Persistent link

Cite this

Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., Ravandi, F., Erba, H. P., Byrne, M., Michaelis, L., Topp, M. S., Vey, N., Ciceri, F., Carrabba, M. G., Paolini, S., ... DiPersio, J. F. (2021). Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 137(6), 751-762. https://doi.org/10.1182/blood.2020007732

@article{cd118d8345284c3ba3e778518dbdfac2,

title = "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia",

abstract = "Approximately 50\% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure IPIF1) or relapse after",

keywords = "CYTOKINE RELEASE SYNDROME, RECEPTOR T-CELLS, MYELODYSPLASTIC SYNDROME, PHASE-II, CYTARABINE, DIAGNOSIS, CRITERIA, RECOMMENDATIONS, BLINATUMOMAB, FLUDARABINE",

author = "Uy, \{Geoffrey L.\} and Ibrahim Aldoss and Foster, \{Matthew C.\} and Sayre, \{Peter H.\} and Wieduwilt, \{Matthew J.\} and Advani, \{Anjali S.\} and Godwin, \{John E.\} and Arellano, \{Martha L.\} and Sweet, \{Kendra L.\} and Ashkan Emadi and Farhad Ravandi and Erba, \{Harry P.\} and Michael Byrne and Laura Michaelis and Topp, \{Max S.\} and Norbert Vey and Fabio Ciceri and Carrabba, \{Matteo Giovanni\} and Stefania Paolini and Huls, \{Gerwin A.\} and Mojca Jongen-Lavrencic and Martin Wermke and Patrice Chevallier and Emmanuel Gyan and Christian Recher and Stiff, \{Patrick J.\} and Pettit, \{Kristen M.\} and Bob Lowenberg and Church, \{Sarah E.\} and Erica Anderson and Jayakumar Vadakekolathu and Marianne Santaguida and Rettig, \{Michael P.\} and John Muth and Teia Curtis and Erin Fehr and Kuo Guo and Jian Zhao and Ouiam Bakkacha and Kenneth Jacobs and Kathy Tran and Patrick Kaminker and Maya Kostova and Ezio Bonvini and Walter, \{Roland B.\} and Davidson-Moncada, \{Jan K.\} and Sergio Rutella and DiPersio, \{John F.\}",

year = "2021",

month = feb,

day = "11",

doi = "10.1182/blood.2020007732",

language = "English",

volume = "137",

pages = "751--762",

journal = "Blood",

issn = "0006-4971",

publisher = "AMER SOC HEMATOLOGY",

number = "6",

}

Uy, GL, Aldoss, I, Foster, MC, Sayre, PH, Wieduwilt, MJ, Advani, AS, Godwin, JE, Arellano, ML, Sweet, KL, Emadi, A, Ravandi, F, Erba, HP, Byrne, M, Michaelis, L, Topp, MS, Vey, N, Ciceri, F, Carrabba, MG, Paolini, S, Huls, GA, Jongen-Lavrencic, M, Wermke, M, Chevallier, P, Gyan, E, Recher, C, Stiff, PJ, Pettit, KM, Lowenberg, B, Church, SE, Anderson, E, Vadakekolathu, J, Santaguida, M, Rettig, MP, Muth, J, Curtis, T, Fehr, E, Guo, K, Zhao, J, Bakkacha, O, Jacobs, K, Tran, K, Kaminker, P, Kostova, M, Bonvini, E, Walter, RB, Davidson-Moncada, JK, Rutella, S & DiPersio, JF 2021, 'Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia', Blood, vol. 137, no. 6, pp. 751-762. https://doi.org/10.1182/blood.2020007732

TY - JOUR

T1 - Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

AU - Uy, Geoffrey L.

AU - Aldoss, Ibrahim

AU - Foster, Matthew C.

AU - Sayre, Peter H.

AU - Wieduwilt, Matthew J.

AU - Advani, Anjali S.

AU - Godwin, John E.

AU - Arellano, Martha L.

AU - Sweet, Kendra L.

AU - Emadi, Ashkan

AU - Ravandi, Farhad

AU - Erba, Harry P.

AU - Byrne, Michael

AU - Michaelis, Laura

AU - Topp, Max S.

AU - Vey, Norbert

AU - Ciceri, Fabio

AU - Carrabba, Matteo Giovanni

AU - Paolini, Stefania

AU - Huls, Gerwin A.

AU - Jongen-Lavrencic, Mojca

AU - Wermke, Martin

AU - Chevallier, Patrice

AU - Gyan, Emmanuel

AU - Recher, Christian

AU - Stiff, Patrick J.

AU - Pettit, Kristen M.

AU - Lowenberg, Bob

AU - Church, Sarah E.

AU - Anderson, Erica

AU - Vadakekolathu, Jayakumar

AU - Santaguida, Marianne

AU - Rettig, Michael P.

AU - Muth, John

AU - Curtis, Teia

AU - Fehr, Erin

AU - Guo, Kuo

AU - Zhao, Jian

AU - Bakkacha, Ouiam

AU - Jacobs, Kenneth

AU - Tran, Kathy

AU - Kaminker, Patrick

AU - Kostova, Maya

AU - Bonvini, Ezio

AU - Walter, Roland B.

AU - Davidson-Moncada, Jan K.

AU - Rutella, Sergio

AU - DiPersio, John F.

PY - 2021/2/11

Y1 - 2021/2/11

N2 - Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure IPIF1) or relapse after

AB - Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure IPIF1) or relapse after

KW - CYTOKINE RELEASE SYNDROME

KW - RECEPTOR T-CELLS

KW - MYELODYSPLASTIC SYNDROME

KW - PHASE-II

KW - CYTARABINE

KW - DIAGNOSIS

KW - CRITERIA

KW - RECOMMENDATIONS

KW - BLINATUMOMAB

KW - FLUDARABINE

U2 - 10.1182/blood.2020007732

DO - 10.1182/blood.2020007732

M3 - Article

SN - 0006-4971

VL - 137

SP - 751

EP - 762

JO - Blood

JF - Blood

IS - 6

ER -

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this